BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND uPA AND Prognosis
53 results:

  • 1. ALG3 Promotes Peritoneal Metastasis of Ovarian cancer through Increasing Interaction of α1,3-mannosylated upaR and ADAM8.
    Cui X; Pei X; Wang H; Feng P; Qin H; Liu S; Yan Q; Liu J
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231102
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid cancer Cell Lines.
    Baldini E; Presutti D; Favoriti P; Santini S; Papoff G; Tuccilli C; Carletti R; Di Gioia C; Lori E; Ferent IC; Gagliardi F; Catania A; Pironi D; Tripodi D; D'Andrea V; Sorrenti S; Ruberti G; Ulisse S
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409084
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP14/TGF-β axis, which is inhibited by 4-acetyl-antroquinonol B treatment.
    Wu CZ; Chu YC; Lai SW; Hsieh MS; Yadav VK; Fong IH; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen JS
    Phytomedicine; 2022 Jun; 100():154062. PubMed ID: 35366491
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Urokinase Plasminogen Activation System in Pancreatic cancer: Prospective Diagnostic and Therapeutic Targets.
    Kumar AA; Buckley BJ; Ranson M
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204653
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Downregulation of SPINK13 Promotes Metastasis by Regulating upa in Ovarian cancer Cells.
    Cai S; Zhang P; Dong S; Li L; Cai J; Xu M
    Cell Physiol Biochem; 2018; 45(3):1061-1071. PubMed ID: 29439245
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.
    Harris NLE; Vennin C; Conway JRW; Vine KL; Pinese M; Cowley MJ; Shearer RF; Lucas MC; Herrmann D; Allam AH; Pajic M; Morton JP; ; Biankin AV; Ranson M; Timpson P; Saunders DN
    Oncogene; 2017 Jul; 36(30):4288-4298. PubMed ID: 28346421
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The Transient Receptor Potential Melastatin 7 Channel Regulates Pancreatic cancer Cell Invasion through the Hsp90α/upa/MMP2 pathway.
    Rybarczyk P; Vanlaeys A; Brassart B; Dhennin-Duthille I; Chatelain D; Sevestre H; Ouadid-Ahidouch H; Gautier M
    Neoplasia; 2017 Apr; 19(4):288-300. PubMed ID: 28284058
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?
    Zhu H; Ying L; Tang W; Yang X; Sun B
    Radiol Med; 2017 May; 122(5):319-326. PubMed ID: 28176217
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. cRGD inhibits vasculogenic mimicry formation by down-regulating upa expression and reducing EMT in ovarian cancer.
    Tang J; Wang J; Fan L; Li X; Liu N; Luo W; Wang J; Wang Y; Wang Y
    Oncotarget; 2016 Apr; 7(17):24050-62. PubMed ID: 26992227
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.
    Su M; Chang W; Wang D; Cui M; Lin Y; Wu S; Xu T
    Oncol Rep; 2015 Sep; 34(3):1337-44. PubMed ID: 26166362
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
    Mashiko S; Kitatani K; Toyoshima M; Ichimura A; Dan T; Usui T; Ishibashi M; Shigeta S; Nagase S; Miyata T; Yaegashi N
    Cancer Biol Ther; 2015; 16(2):253-60. PubMed ID: 25587663
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. miR-193b directly targets STMN1 and upa genes and suppresses tumor growth and metastasis in pancreatic cancer.
    Li J; Kong F; Wu K; Song K; He J; Sun W
    Mol Med Rep; 2014 Nov; 10(5):2613-20. PubMed ID: 25215905
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study.
    Battista MJ; Mantai N; Sicking I; Cotarelo C; Weyer V; Lebrecht A; Solbach C; Schmidt M
    Oncol Rep; 2014 May; 31(5):2213-9. PubMed ID: 24627004
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patient].
    Gershteĭn ES; Kushlinskiĭ NE
    Vestn Ross Akad Med Nauk; 2013; (5):16-27. PubMed ID: 24000664
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Multifunctional roles of urokinase plasminogen activator (upa) in cancer stemness and chemoresistance of pancreatic cancer.
    Asuthkar S; Stepanova V; Lebedeva T; Holterman AL; Estes N; Cines DB; Rao JS; Gondi CS
    Mol Biol Cell; 2013 Sep; 24(17):2620-32. PubMed ID: 23864708
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
    Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D
    Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The urokinase plasminogen activating system in thyroid cancer: clinical implications.
    Baldini E; Sorrenti S; D'Armiento E; Di Matteo FM; Catania A; Ulisse S
    G Chir; 2012 Oct; 33(10):305-10. PubMed ID: 23095556
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
    Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
    Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Gambogic acid-loaded magnetic Fe(3)O(4) nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1.
    Wang C; Zhang H; Chen Y; Shi F; Chen B
    Int J Nanomedicine; 2012; 7():781-7. PubMed ID: 22393285
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.